Business Segments · Selling, general and administrative expenses
Cardiovascular — Selling, general and administrative expenses
Boston Scientific Cardiovascular — Selling, general and administrative expenses decreased by 3.1% to $959M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 9.9%, from $873M to $959M. Over 3 years (FY 2022 to FY 2025), Cardiovascular — Selling, general and administrative expenses shows an upward trend with a 14.6% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementSegment
CategoryEfficiency
SignalLower is better
VolatilityStable
First reportedQ1 2022
Last reportedQ1 2026May 1, 2026
How to read this metric
High spending may be necessary for market penetration, but excessive growth relative to revenue can signal inefficiency.
Detailed definition
Represents the operating costs incurred to support the Cardiovascular segment, including sales force compensation, marke...
Peer comparison
Standard SG&A expense reporting for business segments.
Metric ID:
bsx_segment_cardiovascular_selling_general_and_administrative_expensesHistorical Data
17 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $613.5M | $613.5M | $613.5M | $613.5M | $695.25M | $695.25M | $695.25M | $695.25M | $740M | $796M | $791M | $874M | $873M | $908M | $920M | $990M | $959M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +13.3% | +0.0% | +0.0% | +0.0% | +6.4% | +7.6% | -0.6% | +10.5% | -0.1% | +4.0% | +1.3% | +7.6% | -3.1% |
| YoY Change | — | — | — | — | +13.3% | +13.3% | +13.3% | +13.3% | +6.4% | +14.5% | +13.8% | +25.7% | +18.0% | +14.1% | +16.3% | +13.3% | +9.9% |
Range$613.5M – $990M
CAGR+11.8%
Avg YoY Growth+14.2%
Median YoY Growth+13.3%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Boston Scientific's cardiovascular — selling, general and administrative expenses?
- Boston Scientific (BSX) reported cardiovascular — selling, general and administrative expenses of $959M in Q1 2026.
- How has Boston Scientific's cardiovascular — selling, general and administrative expenses changed year-over-year?
- Boston Scientific's cardiovascular — selling, general and administrative expenses increased by 9.9% year-over-year, from $873M to $959M.
- What is the long-term trend for Boston Scientific's cardiovascular — selling, general and administrative expenses?
- Over 3 years (2022 to 2025), Boston Scientific's cardiovascular — selling, general and administrative expenses has grown at a 14.6% compound annual growth rate (CAGR), from $2.45B to $3.69B.
- What does cardiovascular — selling, general and administrative expenses mean?
- The total operating costs for sales, marketing, and administration in the Cardiovascular segment.